Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units
Jazyk angličtina Země Itálie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
21811750
Knihovny.cz E-zdroje
- MeSH
- amikacin farmakologie MeSH
- antibakteriální látky farmakologie MeSH
- cefoperazon farmakologie MeSH
- ceftazidim farmakologie MeSH
- ciprofloxacin farmakologie MeSH
- gentamiciny farmakologie MeSH
- jednotky intenzivní péče * MeSH
- kyselina penicilanová analogy a deriváty farmakologie MeSH
- mikrobiální testy citlivosti MeSH
- mnohočetná bakteriální léková rezistence MeSH
- piperacilin farmakologie MeSH
- Pseudomonas aeruginosa účinky léků MeSH
- sulbaktam farmakologie MeSH
- tazobaktam MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Česká republika MeSH
- Názvy látek
- amikacin MeSH
- antibakteriální látky MeSH
- cefoperazon MeSH
- ceftazidim MeSH
- ciprofloxacin MeSH
- gentamiciny MeSH
- kyselina penicilanová MeSH
- piperacilin MeSH
- sulbaktam MeSH
- tazobaktam MeSH
Pseudomonas aeruginosa is one of the most frequent and dangerous pathogens involved in the etiology of severe nosocomial infections. A retrospective observational study was conducted at all intensive care units of the University Hospital in Olomouc, Czech Republic (155 ICU beds). Complete antibiotic utilization data of the ICUs in the period of 1999 to 2008 were processed according to ATC/DDD system and expressed in defined daily doses per 100 bed-days (DBD). Utilization of meropenem, imipenem, ciprofloxacin, ofloxacin, pefloxacin, gentamicin, amikacin, ceftazidime, cefoperazone, cefoperazone/sulbactam and piperacillin/tazobactam was measured. Pseudomonas aeruginosa strains were isolated from clinical material obtained from patients hospitalized in ICUs. During the ten-year period, utilization of the entire group of antibiotics monitored grew. It increased from 23.52 DBD in 1999 to 27.48 DBD in 2008 with a peak of 33.04 DBD in 2007. P. aeruginosa accounted for as much as 42% of pneumonias and 23% of surgical wound infections. Our results show that P. aeruginosa strains became gradually resistant to all antibiotics used in the treatment of the infections caused by them, with the exception of amikacin and piperacillin/tazobactam.